Pharma Pulse 6/27/24: Pharmacy Deserts & Underserved/Rural Communities, GoodRx Launches New “Prescription Cost Tracker” & more


The latest news for pharma industry insiders.

Pharmacy Deserts & Underserved/Rural Communities

In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, speaks about the specific challenges that pharmacy deserts becoming a national issue presents for rural and underserved areas. Plus a discussion of which alternative solutions can help ensure continued access to medications for all.

Researchers Develop Bread With Probiotic Properties That Reduce Asthma Symptoms in Mice

Mice with asthma that were fed bread with Saccharomyces cerevisiae UFMG A-905 yeast showed reduced airway inflammation and decreased IL-5 and IL-13 concentrations, and effects increased when combined with microcapsules.

AI Work Assistants Need a Lot of Handholding

Getting full value out of AI workplace assistants is turning out to require a heavy lift from enterprises. ‘It has been more work than anticipated,’ says one CIO.

GoodRx Launches New “Prescription Cost Tracker” to Spotlight Key Factors Driving Out-of-Pocket Medication Costs in the U.S.

GoodRx debuted its new Prescription Cost Tracker where it will monitor out-of-pocket prescription spending trends in the U.S. to help Americans better understand prescription affordability and price transparency. Helping Americans get the healthcare they need starts with tackling the barriers of costs and coverage, and there are three key factors driving the financial burden for prescriptions: high medication costs, reduced insurance coverage and increased friction. The Prescription Cost Tracker, which will be regularly updated to reflect the latest available data, helps examine these factors and illustrate why 51 million Americans leave prescription medications unfilled every month and many more face high costs at the counter.

Cencora on LinkedIn

Balancing patient relevancy with payers’ expectations is a critical industry challenge.

VP of Cell and Gene Therapy Lung-I Cheng speaks about this and other industry issues, as well as about the positive work the FDA is doing with cell and gene therapy, in a recent Pharmaceutical Commerce Magazine interview:

Have news you want us to share in Pharma Pulse? Reach out to Social

Media Editor Miranda Schmalfuhs

© 2024 MJH Life Sciences

All rights reserved.